Researchers conducted a study to determine if self-reported sleep deprivation is associated with an increased risk of coronary events.
FDA Accepts sBLA for Evkeeza for Children with Rare High Cholesterol
November 30th 2022If approved, Evkeeza would be the first treatment to help children as young as 5 years old control high LDL cholesterol caused by homozygous familial hypercholesterolemia. The FDA target action date is March 30, 2023.
2 Clarke Drive
Cranbury, NJ 08512